Dr. Frederick Haraka is a research scientist at Ifakara Health Institute, working within the Tuberculosis research group. Prior to joining the institute in 2010, Dr. Haraka obtained his Medical Degree from the Muhimbili University of Health and Allied sciences, Tanzania, in 2009, and in 2013 received his Master’s degree in Applied Epidemiology from the University of Nottingham in the UK, with merit. He is currently registered as a PhD candidate in Epidemiology at the Swiss Tropical and Public Health institute, University of Basel in Switzerland. Dr. Haraka has experience in leading and implementing Good Clinical Practice (GCP), regulated clinical trials of Tuberculosis treatment regimen, vaccines and diagnostics. He is also actively involved in designing, implementing and analysing observational studies in TB and HIV. Following this interest, Dr. Haraka has numerous publications in both local and international journals focused around issues on TB and HIV. Dr. Haraka is currently a site Principal Investigator, leading a phase 2 multi-centre TB treatment regimen trial funded and sponsored by Global alliance for tuberculosis drug development, titled “A Phase 2 Open‐Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of combinations of bedaquiline, moxifloxacin, PA‐824 and pyrazinamide during 8 weeks of treatment in Adult Subjects with Newly Diagnosed Drug‐Sensitive or Multi Drug‐Resistant, Smear‐Positive Pulmonary Tuberculosis”. Beyond his scientific research, Dr Haraka is a part-time lecturer at International Medical and Technological University and Hubert Kairuki Memorial University, and mentor to junior researchers in the Institutes TB research group.